Drug intelligence / Profile preview

milrebrutinib

Development stage: Unknown
Lead developer: Carna Biosciences
Modality: Small Molecules
Administration: Oral

Overview

BN102 (milrebrutinib) is a novel, next-generation, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. It is highly selective and orally bioavailable, designed to inhibit both wild-type and C481S mutant forms of BTK. The drug was initially developed by Carna Biosciences and is being further developed by BioNova for the treatment of hematologic malignancies such as Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin Lymphoma (NHL). Its mechanism of action involves non-covalent inhibition of BTK, which plays a critical role in B-cell receptor signaling pathways implicated in these cancers[1][3][5].

Other names: milrebrutinibBN102BN-102BN 102

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on milrebrutinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on milrebrutinib.

Explore the full profile